摘要
Differentapproachesfortreatinglungcancerhavebeendevelopedovertime,includingchemotherapy,radiotherapyandtargetedtherapiesagainstactivatingmutations.Lately,betterunderstandingoftheroleoftheimmunologicalsystemintumorcontrolhasopenedmultipledoorstoimplementdifferentstrategiestoenhanceimmuneresponseagainstcancercells.Itisknownthattumorcellseludeimmuneresponsebyseveralmechanisms.Thedevelopmentofmonoclonalantibodiesagainstthecheckpointinhibitorprogrammedcelldeathprotein1(PD-1)anditsligand(PD-L1),onTcells,hasledtohighactivityincancerpatientswithlonglastingresponses.Nivolumab,anantiPD-1inhibitor,hasbeenrecentlyapprovedforthetreatmentofsquamouscelllungcancerpatients,giventhesurvivaladvantagedemonstratedinaphaseIIItrial.Pembrolizumab,anotherantiPD-1antibody,hasreceivedFDAbreakthroughtherapydesignationfortreatmentofnon-smallcelllungcancer(NSCLC),supportedbydatafromaphaseItrial.ClinicaltrialswithantiPD-1/PD-L1antibodiesinNSCLChavedemonstratedverygoodtolerabilityandactivity,withresponseratesaround20%andamediandurationofresponseof18months.
出版日期
2015年03月13日（中国期刊网平台首次上网日期，不代表论文的发表时间）
